Individual patient risk stratification of high-risk neuroblastomas using a two-gene score suited for clinical use.
Int J Cancer
; 137(4): 868-77, 2015 Aug 15.
Article
em En
| MEDLINE
| ID: mdl-25652004
Several gene expression-based prognostic signatures have been described in neuroblastoma, but none have successfully been applied in the clinic. Here we have developed a clinically applicable prognostic gene signature, both with regards to number of genes and analysis platform. Importantly, it does not require comparison between patients and is applicable amongst high-risk patients. The signature is based on a two-gene score (R-score) with prognostic power in high-stage tumours (stage 4 and/or MYCN-amplified diagnosed after 18 months of age). QPCR-based and array-based analyses of matched cDNAs confirmed cross platform (array-qPCR) transferability. We also defined a fixed cut-off value identifying prognostically differing subsets of high-risk patients on an individual patient basis. This gene expression signature independently contributes to the current neuroblastoma classification system, and if prospectively validated could provide further stratification of high-risk patients, and potential upfront identification of a group of patients that are in need of new/additional treatment regimens.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Detecção Precoce de Câncer
/
Transcriptoma
/
Proteínas de Neoplasias
/
Neuroblastoma
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
/
Screening_studies
Limite:
Child, preschool
/
Humans
/
Infant
Idioma:
En
Revista:
Int J Cancer
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
Suécia